Giselle Mosnaim, MD, an allergist and immunologist at Endeavor Health, discusses Rhapsido® (remibrutinib), a new FDA-approved oral therapy for chronic ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation.

The risk for MASLD was significantly reduced by 14.7 and 13.5%, respectively, by replacing 330g/day of sugar-sweetened beverages or low- or non-sugar-sweetened beverages with water.

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Ambient trichloroethylene (TCE) is associated with an increased risk for Parkinson disease (PD), according to a study published online October 1 in Neurology. B ...

Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.

The same price is already available on Novo Nordisk’s direct-to-consumer website, as well as at Walmart and CVS.

Positivity decreased for 2vHPV, 4vHPV, and 9vHPV for vaccinated and unvaccinated participants from 2006 to 2023.

CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; ...

The table below is a review of notable updates that occurred in September 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.